Pauline Yeo

810 total citations
24 papers, 495 citations indexed

About

Pauline Yeo is a scholar working on Oncology, Molecular Biology and Atomic and Molecular Physics, and Optics. According to data from OpenAlex, Pauline Yeo has authored 24 papers receiving a total of 495 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Oncology, 7 papers in Molecular Biology and 5 papers in Atomic and Molecular Physics, and Optics. Recurrent topics in Pauline Yeo's work include Histone Deacetylase Inhibitors Research (6 papers), Semiconductor Quantum Structures and Devices (4 papers) and Peptidase Inhibition and Analysis (4 papers). Pauline Yeo is often cited by papers focused on Histone Deacetylase Inhibitors Research (6 papers), Semiconductor Quantum Structures and Devices (4 papers) and Peptidase Inhibition and Analysis (4 papers). Pauline Yeo collaborates with scholars based in Singapore, Canada and United States. Pauline Yeo's co-authors include Kantharaj Ethirajulu, S. P. Watkins, Xinji Xu, Xiaofeng Wu, Miroslav Dvořák, C. R. Bolognesi, Kanda Sangthongpitag, Veronica Novotny‐Diermayr, Kee Chuan Goh and Man He and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Journal of Applied Physics.

In The Last Decade

Pauline Yeo

24 papers receiving 472 citations

Peers

Countries citing papers authored by Pauline Yeo

Since Specialization

Citations

This map shows the geographic impact of Pauline Yeo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Pauline Yeo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Pauline Yeo more than expected).

Fields of papers citing papers by Pauline Yeo

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Pauline Yeo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Pauline Yeo. The network helps show where Pauline Yeo may publish in the future.

Co-authorship network of co-authors of Pauline Yeo

This figure shows the co-authorship network connecting the top 25 collaborators of Pauline Yeo. A scholar is included among the top collaborators of Pauline Yeo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Pauline Yeo. Pauline Yeo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	First‐in‐Human, Healthy Volunteers Integrated Protocol of ETC‐206, an Oral Mnk 1/2 Kinase Inhibitor Oncology Drug 2019 ·Clinical and Translational Science ·Vincenzo Teneggi, Veronica Novotny‐Diermayr, (unknown), (unknown), Pauline Yeo, Kantharaj Ethirajulu, (unknown), Stéphanie Blanchard, Ranjani Nellore, (unknown), Roberto Goméni, (unknown), (unknown), (unknown), Yang Cao, Alex Matter	11
2	Phase I extension study of ETC-159 an oral PORCN inhibitor administered with bone protective treatment, in patients with advanced solid tumours 2018 ·Annals of Oncology ·David S.P. Tan, Matthew Chau Hsien Ng, Vivek Subbiah, Wells A. Messersmith, Vincenzo Teneggi, (unknown), Kantharaj Ethirajulu, Pauline Yeo, (unknown), (unknown), Stéphanie Blanchard, Ranjani Nellore, (unknown), (unknown), (unknown), Jeffrey Hill, Babita Madan, David M. Virshup, A. Matter	12
3	152O A phase 1, first-in-human dose escalation study of ETC-159 in advanced or metastatic solid tumours 2016 ·Annals of Oncology ·Vincenzo Teneggi, Matthew Ng, David S.P. Tan, Vivek Subbiah, Colin D. Weekes, (unknown), Kantharaj Ethirajulu, Pauline Yeo, (unknown), (unknown), Stéphanie Blanchard, Ranjani Nellore, (unknown), Jeffrey Hill, David M. Virshup, Babita Madan, A. Matter	10
4	Safety and immunogenicity of a virus-like particle pandemic influenza A (H1N1) 2009 vaccine: Results from a double-blinded, randomized Phase I clinical trial in healthy Asian volunteers 2014 ·Vaccine ·Jenny G. Low, Lawrence Lee, Eng Eong Ooi, Kantharaj Ethirajulu, Pauline Yeo, Alex Matter, John E. Connolly, David Skibinski, Philippe Saudan, Martin F. Bachmann, Brendon J. Hanson, Qingshu Lu, Sebastian Maurer‐Stroh, Sam Lim, Veronica Novotny‐Diermayr	60
5	Preclinical Metabolism and Pharmacokinetics of SB1317 (TG02), a Potent CDK/JAK2/FLT3 Inhibitor 2012 ·Drug Metabolism Letters ·Mohammad Pasha, Ramesh Jayaraman, Venkatesh Pilla Reddy, Pauline Yeo, (unknown), Anthony P. Williams, Kee Chuan Goh, Kantharaj Ethirajulu	17
6	Preclinical Metabolism and Disposition of SB939 (Pracinostat), an Orally Active Histone Deacetylase Inhibitor, and Prediction of Human Pharmacokinetics 2011 ·Drug Metabolism and Disposition ·Ramesh Jayaraman, Venkatesh Pilla Reddy, Mohammad Pasha, Haishan Wang, Kanda Sangthongpitag, Pauline Yeo, (unknown), Xiaofeng Wu, Xin Liu, (unknown), Lee Sun New, Kantharaj Ethirajulu	17
7	SB939, a Novel Potent and Orally Active Histone Deacetylase Inhibitor with High Tumor Exposure and Efficacy in Mouse Models of Colorectal Cancer 2010 ·Molecular Cancer Therapeutics ·Veronica Novotny‐Diermayr, Kanda Sangthongpitag, (unknown), Xiaofeng Wu, Nina Sausgruber, Pauline Yeo, Gediminas Greicius, Sven Pettersson, (unknown), Yung Kiang Loh, Zahid Bonday, Kee Chuan Goh, Hannes Hentze, Stefan Hart, Haishan Wang, Kantharaj Ethirajulu, Jeanette M. Wood	109
8	83 POSTER A robust and quantitative biomarker assay for SB939, a potent, orally-active HDAC inhibitor 2008 ·European Journal of Cancer Supplements ·Veronica Novotny‐Diermayr, (unknown), (unknown), (unknown), Yung Kiang Loh, Nina Sausgruber, Pauline Yeo, Kantharaj Ethirajulu, (unknown)	2
9	Development and validation of high‐performance liquid chromatography–tandem mass spectrometry assay for 6‐(3‐benzoyl‐ureido)‐hexanoic acid hydroxyamide, a novel HDAC inhibitor, in mouse plasma for pharmacokinetic studies 2007 ·Biomedical Chromatography ·Pauline Yeo, Xin Liu, (unknown), Lee Sun New, (unknown), Xiaofeng Wu, Venkatesh Paramesh, Kantharaj Ethirajulu	31
10	In Vitro Phase I Cytochrome P450 Metabolism, Permeability and Pharmacokinetics of SB639, a Novel Histone Deacetylase Inhibitor in Preclinical Species 2007 ·Biological and Pharmaceutical Bulletin ·(unknown), (unknown), (unknown), Lee Sun New, Xin Liu, Mohammad Pasha, Kanda Sangthongpitag, Pauline Yeo, Kantharaj Ethirajulu	22
11	Pharmacokinetic and Pharmacodynamic Properties of SB1317, a Potent and Orally Active Multi-Kinase Inhibitor. 2007 ·Blood ·Pauline Yeo, Venkatesh Paramesh, (unknown), (unknown), Lee Sun New, Changyong Hu, Kanda Sangthongpitag, Anthony D. William, Kee Chuan Goh, Jeanette M. Wood, Kantharaj Ethirajulu	1
12	166 POSTER ADME and PK/PD attributes of SB939, a potent orally active HDAC inhibitor 2006 ·European Journal of Cancer Supplements ·Kanda Sangthongpitag, Haishan Wang, Pauline Yeo, (unknown), (unknown), (unknown), Peng Zeng, Xiaofeng Wu, (unknown), Kantharaj Ethirajulu	2
13	Interfacial reaction between Sn-rich solders and Ni-based metallization 2004 ·Thin Solid Films ·Man He, (unknown), Pauline Yeo, Guo-Jun Qi, Zhong Chen	39
14	Infrared single wavelength gas composition monitoring for metalorganic vapour-phase epitaxy 2000 ·Journal of Crystal Growth ·S. P. Watkins, (unknown), Jonathan Hu, Pauline Yeo, (unknown), N. J. Mason, R. J. Nicholas, P.J. Walker	16
15	Time-resolved reflectance difference spectroscopy of InAs growth under alternating flow conditions 1998 ·Journal of Crystal Growth ·Richard Arès, Jonathan Hu, Pauline Yeo, S. P. Watkins	2
16	Growth mechanisms in atomic layer epitaxy of GaAs 1998 ·Journal of Applied Physics ·Richard Arès, S. P. Watkins, Pauline Yeo, (unknown), Paul O’Brien, Anthony C. Jones	9
17	Phosphorus Passivation of GaAs 1998 ·MRS Proceedings ·S. P. Watkins, Xiangang Xu, Jonathan Hu, Richard Arès, Pauline Yeo, (unknown), M. L. W. Thewalt, C. R. Bolognesi, A. J. SpringThorpe	2
18	Trisneopentylgallium as a precursor for atomic layer epitaxy of GaAs 1997 ·Journal of Electronic Materials ·Pauline Yeo, Richard Arès, S. P. Watkins, (unknown), Paul O’Brien, Anthony C. Jones	6
19	Physiological studies of exopolysaccharide production from the basidiomycete Pleurotus sp. florida 1994 ·Enzyme and Microbial Technology ·(unknown), Pauline Yeo, Tajalli Keshavarz, Sibel Roller, Chantell S. Evans	33
20	Visual evoked responses in diabetes. 1987 ·PubMed ·Keith S. Millingen, Pauline Yeo, (unknown)	3

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact